Alpha 2.0
Login Register
» Articles » PMID: 5814426

Bioassay for Hamycin and Amphotericin B in Serum and Other Biological Fluids

Overview
Journal Appl Microbiol
Publisher American Society for Microbiology
Specialty Microbiology
Date 1969 Apr 1
PMID 5814426
Citations 18
Authors
S Shadomy
J A McCay
S I Schwartz
Affiliations
Soon will be listed here.
Abstract

A bioassay suitable for measuring concentrations of the polyene antifungal agents hamycin and amphotericin B in biological fluids is described. By using Paecilomyces varioti as the indicator organism, sensitivity of the bioassay was found to be in the range of 0.01 to 0.02 mug/ml. A linear dose-response curve was obtained with amphotericin B; the curve for hamycin was curvilinear. In a series of assays, hamycin serum levels in the range of 0.01 to 3.5 mug/ml were measured; with amphotericin B, serum levels in the range of 0.015 to 0.175 mug/ml were measured in patients receiving orthodox intravenous medication and as high as 9.0 mug/ml in one patient treated with extraordinarily high doses of the drug.

Citing Articles

Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.

Elefanti A, Mouton J, Verweij P, Zerva L, Meletiadis J Antimicrob Agents Chemother. 2014; 58(4):2356-62.

PMID: 24514094 PMC: 4023763. DOI: 10.1128/AAC.02661-13.

Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Al-Saigh R, Siopi M, Siafakas N, Velegraki A, Zerva L, Meletiadis J Antimicrob Agents Chemother. 2013; 57(8):3713-8.

PMID: 23716054 PMC: 3719712. DOI: 10.1128/AAC.02484-12.

Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Meletiadis J, Al-Saigh R, Velegraki A, Walsh T, Roilides E, Zerva L Antimicrob Agents Chemother. 2011; 56(1):403-10.

PMID: 22064546 PMC: 3256091. DOI: 10.1128/AAC.00662-11.

In Vivo Susceptibility of Cryptococcus neoformans to Hamycin, Amphotericin B, and 5-Fluorocytosine.

Shadomy S, Shadomy H, UTZ J Infect Immun. 1970; 1(1):128-34.

PMID: 16557685 PMC: 415864. DOI: 10.1128/iai.1.1.128-134.1970.

Experimental intraabdominal candidiasis in rabbits: therapy with low-total-dose intravenous amphotericin B.

Bayer A, Edwards Jr J, Guze L Antimicrob Agents Chemother. 1981; 19(1):179-84.

PMID: 7247356 PMC: 181378. DOI: 10.1128/AAC.19.1.179.

References
1.
PIGGOTT W, WILLIAMS Jr T, EMMONS C . Bioassay for hamycin. Antimicrob Agents Chemother (Bethesda). 1965; 5:353-7. View
2.
EMMONS C, PIGGOTT W . Bioassay of the antifungal agent X-5079C in serum of patients. Am Rev Respir Dis. 1961; 84:534-7. DOI: 10.1164/arrd.1961.84.4.534. View
3.
Gerke J, MADIGAN M . Amphotericin B and other polyene antifungal antibiotics: photometric assay and factors influencing activity. Antibiot Chemother (Northfield). 1961; 11:227-37. View
4.
Kramer J, KIRSHBAUM A . Cylinder plate assays for amphotericin B in dosage forms and body fluids. Antibiot Chemother (Northfield). 1960; 10:188-92. View